Therapeutic strategies for neurodegenerative disorders have commonly targeted individual
aspects of the disease pathogenesis to little success. Neurodegenerative diseases …

Late-onset Alzheimer's disease (LOAD) is the most frequent cause of dementia in older
persons. Subjects affected by type 2 diabetes mellitus (T2DM) are at higher risk of vascular …

The lack of effective treatments for dementia has led to explore the potential of antidiabetic
agents as a possible approach. This cross-sectional and population-based study aimed to …

Modern anticoagulation therapy has dramatically reduced the risk of stroke and systemic
thromboembolism in people with atrial fibrillation (AF). However, AF still impairs quality of …

Alzheimer's Disease (AD) is a global chronic disease in adults with beta-amyloid (Aβ)
deposits and hyperphosphorylated tau protein as the pathologic characteristics. Although …

Sodium-glucose cotransporter inhibitor/inhibition (SGLTi), initially approved as a glucose-
lowering therapy for type 2 diabetes, is associated with decreased risks for many of the most …

Background Sulfonylureas are oral glucose‐lowering medications positioned as a second‐
line therapy for type 2 diabetes. Evidence relating them to cognitive decline has been mixed …

Background Metformin has been suggested to reduce dementia risk; however, most
epidemiologic studies have been limited by immortal time bias or confounding due to …

Type 2 diabetes mellitus (T2DM) is a highly prevalent health condition in the aging
population. Older adults with T2DM have higher risks of cardiovascular disease, heart failure …

The nucleotide-binding domain-like receptor protein 3 (NLRP3) inflammasome in the kidney
and the heart is increasingly being suggested to play a key role in mediating inflammation …